Odetiglucan is under clinical development by Hibercell and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Odetiglucan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BTH-1677 is under development for the treatment of cutaneous melanoma, advanced indolent non-hodgkin's lymphoma, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-small cell lung cancer, and patients with stage IV KRAS-mutated colorectal cancer, metastatic melanoma, metastatic breast cancer, metastatic triple negative breast cancer, pancreatic ductal adenocarcinoma, metastatic pancreatic adenocarcinoma and liver metastasis. The drug candidate is administered intravenously. It acts by targeting dectin-1, CR3, Fc gamma receptor and is being developed based on QuAD³ Platform. It is a soluble polysaccharide beta 1,3/1,6 glucan and is derived from the cell wall of the yeast Saccharomyces cerevisiae.
It was also under development for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, metastatic colorectal cancer and metastatic colorectal cancer (third-line therapy), chronic lymphocytic leukemia.
Hibercell is a biotechnology company that discovers and develops therapies for treatment of cancer. The company is investigating odetiglucan, an immune modulator candidate that enhances immune functions for treatment of metastatic breast cancer (mBC), pancreatic cancer and liver metastasis. It is also developing adoptive stress response modulator programs, HC-5404 for treatment of renal cell carcinoma, gastric cancer, and others advanced solid tumors; and HC-7366 to treat head and neck, Colorectal, and bladder cancer. Hibercell has developed AI and ML based QuAD3 platform that extracts phenotype and genomic data to understand patient’s outcome with adaptive stress response. The company operates discovery and development facility, clinical facility and laboratory in Ireland and the US. Hibercell is headquartered in New York, the US.
For a complete picture of Odetiglucan’s drug-specific PTSR and LoA scores, buy the report here.